The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis
Open accessAbstract
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) can progress to cirrhosis and hepatic decompensation, but whether genetic variants influence the rate of progression to cirrhosis or are useful in risk stratification among patients with NAFLD is uncertain. METHODS: We included participants from 2 independent cohorts, they Michigan Genomics Initiative (MGI) and UK Biobank (UKBB), who had NAFLD defined by elevated alanine aminotransferase (ALT) levels in the absence of alternative chronic liver disease. The primary predictors were genetic variants and metabolic comorbidities associated with cirrhosis. We conducted time-to-event analyses using Fine-Gray competing risk models. RESULTS: We included 7893 and 46,880 participants from MGI and UKBB, respectively. In univariable analysis, PNPLA3-rs738409-GG genotype, diabetes, obesity, and ALT of ≥2× upper limit of normal were associated with higher incidence rate of cirrhosis in both MGI and UKBB. PNPLA3-rs738409-GG had additive effects with clinical risk factors including diabetes, obesity, and ALT elevations. Among patients with indeterminate fibrosis-4 (FIB4) scores (1.3-2.67), those with diabetes and PNPLA3-rs738409-GG genotype had an incidence rate of cirrhosis comparable to that of patients with high-risk FIB4 scores (>2.67) and 2.9-4.8 times that of patients with diabetes but CC/CG genotypes. In contrast, FIB4 <1.3 was associated with an incidence rate of cirrhosis significantly lower than that of FIB4 of >2.67, even in the presence of clinical risk factors and high-risk PNPLA3 genotype. CONCLUSIONS: PNPLA3-rs738409 genotype and diabetes identified patients with NAFLD currently considered indeterminate risk (FIB4 1.3-2.67) who had a similar risk of cirrhosis as those considered high-risk (FIB4 >2.67). PNPLA3 genotyping may improve prognostication and allow for prioritization of intensive intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall evidence suggests that the PNPLA3 p.I148M and TM6SF2 p.E167K variants are major risk factors for progressive MASLD, and genotyping helps to noninvasively predict progressive MASH, cirrhosis and HCC when considered alongside clinical factors, 194 -196 but accuracy is suboptimal for prediction of liver disease severity and progression at the individual level.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [194]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., & Allen, N. E. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx246 · Cited by 3,979
Clinical use of current polygenic risk scores may exacerbate health disparities
Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M., & Daly, M. J. (2019) · Nature Genetics · doi:10.1038/s41588-019-0379-x · Cited by 2,821
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
Self-citationXiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895
Time-dependent ROC curve analysis in medical research: current methods and applications
Kamarudin, A. N., Cox, T. F., & Kolamunnage‐Dona, R. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0332-6 · Cited by 839
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795
A note on competing risks in survival data analysis
Satagopan, J. M., Ben‐Porat, L., Berwick, M., Robson, M. E., Kutler, D. I., & Auerbach, A. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602102 · Cited by 752
Valenti, L., Al‐Serri, A., Daly, A. K., Galmozzi, E., Rametta, R., Dongiovanni, P., Nobili, V., Mozzi, E., Roviaro, G., Vanni, E., et al. (2010) · Hepatology · doi:10.1002/hep.23622 · Cited by 651
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Competing Risks: A Practical Perspective
Pintilie, M. (2006) · Cited by 442
Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q. M., & Hanratty, B. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003100 · Cited by 434
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Loomba, R. S., Schork, N. J., Chen, C., Bettencourt, R., Bhatt, A., Ang, B., Nguyen, P., Hernandez, C., Richards, L., Salotti, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.011 · Cited by 388
Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385
Allen, A. M., Therneau, T. M., Larson, J. J., Coward, A., Somers, V. K., & Kamath, P. S. (2017) · Hepatology · doi:10.1002/hep.29546 · Cited by 372
Kanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
Confidence intervals for weighted sums of poisson parameters
Dobson, A. J., Kuulasmaa, K., Eberle, E., & Scherer, J. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100317 · Cited by 306
Vujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01078-z · Cited by 205
Grimaudo, S., Pipitone, R. M., Pennisi, G., Celsa, C., Cammà, C., Marco, V. D., Barcellona, M. R., Boemi, R., Enea, M., Giannetti, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.011 · Cited by 152
Direct-to-consumer genetic testing
Horton, R., Crawford, G., Freeman, L., Fenwick, A., Wright, C. F., & Lucassen, A. (2019) · BMJ · doi:10.1136/bmj.l5688 · Cited by 151
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
Marengo, A., Jouness, R. I. K., & Bugianesi, E. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.010 · Cited by 136
A Fast and Accurate Algorithm to Test for Binary Phenotypes and Its Application to PheWAS
Dey, R., Schmidt, E. M., Abecasis, G. R., & Lee, S. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.05.014 · Cited by 135
Emdin, C. A., Haas, M., Ajmera, V. H., Simon, T. G., Homburger, J. R., Neben, C. L., Jiang, L., Wei, W., Feng, Q., Zhou, A. Y., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.011 · Cited by 131
Chen, V. L., Du, X., Chen, Y., Kuppa, A., Handelman, S. K., Vohnoutka, R. B., Peyser, P. A., Palmer, N. D., Bielak, L. F., Halligan, B. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20870-1 · Cited by 131
Stickel, F., Buch, S., Nischalke, H. D., Weiss, K. H., Gotthardt, D. N., Fischer, J., Rosendahl, J., Marot, A., Elamly, M., Casper, M., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0041-8 · Cited by 119
Mapakshi, S. R., Kramer, J. R., Richardson, P., El‐Serag, H. B., & Kanwal, F. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.042 · Cited by 111
Zawistowski, M., Fritsche, L. G., Pandit, A., Vanderwerff, B. R., Patil, S. B., Schmidt, E. M., VandeHaar, P., Willer, C. J., Brummett, C. M., Kheterpal, S., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100257 · Cited by 110
Álvarez, C. S., Graubard, B. I., Thistle, J. E., Petrick, J. L., & McGlynn, K. A. (2019) · Hepatology · doi:10.1002/hep.31040 · Cited by 72
Kitamoto, A., Kitamoto, T., Nakamura, T., Ogawa, Y., Yoneda, M., Hyogo, H., Ochi, H., Mizusawa, S., Ueno, T., Nakao, K., et al. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0052 · Cited by 71
Kim, H., Xiao, X., Byun, J., Jun, G., DeSantis, S. M., Chen, H., Thrift, A. P., El‐Serag, H. B., Kanwal, F., & Amos, C. I. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.34221 · Cited by 69
Barata, L., Feitosa, M. F., Bielak, L. F., Halligan, B. D., Baldridge, A. S., Guo, X., Yerges‐Armstrong, L. M., Smith, A. V., Yao, J., Palmer, N. D., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1353 · Cited by 61
Canbay, A. E., Kachru, N., Haas, J. S., Sowa, J., Meise, D., & Ozbay, A. B. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16016 · Cited by 56
Zhang, X., Wong, G. L., Yip, T. C., Cheung, J. T. K., Tse, Y., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P. S., et al. (2022) · Hepatology · doi:10.1002/hep.32476 · Cited by 56
Genetic variants that associate with cirrhosis have pleiotropic effects on human traits
Chen, V. L., Chen, Y., Du, X., Handelman, S. K., & Speliotes, E. K. (2019) · Liver International · doi:10.1111/liv.14321 · Cited by 54
Sedgwick, P. M. (2010) · BMJ · doi:10.1136/bmj.c4709 · Cited by 53
Palmer, N. D., Kahali, B., Kuppa, A., Chen, Y., Du, X., Feitosa, M. F., Bielak, L. F., O’Connell, J. R., Musani, S. K., Guo, X., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab096 · Cited by 40
Xia, M., Ma, S., Huang, Q., Zeng, H., Ge, J., Xu, W., Wu, Q., Wu, L., Li, X., Ma, H., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16772 · Cited by 38
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study
Barritt, A. S., Watkins, S. E., Gitlin, N., Klein, S., Lok, A. S.-F., Loomba, R. S., Schoen, C., Reddy, K. R., Trinh, H. N., Mospan, A. R., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1689 · Cited by 34
Burkholder, D. A., Moran, I. J., DiBattista, J. V., Lok, A. S.-F., Parikh, N. D., & Chen, V. L. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07282-x · Cited by 28
Serper, M., Vujković, M., Kaplan, D. E., Carr, R. M., Lee, K. M., Shao, Q., Miller, D. R., Reaven, P. D., Phillips, L. S., O’Donnell, C. J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237430 · Cited by 27
Sedgwick, P. M. (2010) · BMJ · doi:10.1136/bmj.c4804 · Cited by 25
DiBattista, J. V., Burkholder, D. A., Lok, A. S.-F., & Chen, V. L. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07415-w · Cited by 17
Hosmer (1997) · doi:10.1002/(sici)1097-0258(19970515)16:9
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Huang, D. Q., Noureddin, N., Ajmera, V. H., Amangurbanova, M., Bettencourt, R., Truong, E., Gidener, T., Siddiqi, H., Majzoub, A. M., Nayfeh, T., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00157-7 · Cited by 198
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 85
Chen, V. L., Du, X., Oliveri, A., Chen, Y., Kuppa, A., Halligan, B. D., Province, M. A., & Speliotes, E. K. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.045 · Cited by 51
Metadata
- Authors
- Chen, V. L., Oliveri, A., Miller, M. J., Wijarnpreecha, K., Du, X., Chen, Y., Cushing, K. C., Lok, A. S., & Speliotes, E. K.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Chen, Vincent L.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 164
- Issue
- 6
- Pages
- 966-977.e17
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC10550206
- OpenAlex
- W4319442654
- Cited by
- 108
- References
- 54
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 15
- FWCI
- 21.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, other-oa)
- Funders
- National Institutes of Health
- NIDDK (K08 DK132312, R01 DK106621, R01 DK107904)
- American Association for the Study of Liver Diseases
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, liver cirrhosis, PNPLA3, rs738409, genetic risk stratification, diabetes mellitus, FIB-4, liver fibrosis, alanine aminotransferase, obesity, disease progression, outcome prediction
- MeSH terms
- Acyltransferases, Diabetes Mellitus, Genotype, Humans, Liver Cirrhosis, Obesity, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Phospholipases A2, Calcium-Independent, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
